ENDPOINTS

Digital health dealmaking is heating up

We’re in dealmaking season for publicly traded digital health companies. In ...

Updated: Hospital group blasts proposed 340B rebate mod...

A trade group representing 1,600 hospitals says 340B rebate models proposed by m...

Roche heads to FDA with Gazyva results in a form of lupus

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech f...

Personify Health shares 2024 revenue, profitability

Personify Health, which sells healthcare spending management services to employe...

Pfizer hires Novartis oncology exec to steer its cancer...

After promoting its oncology officer Chris Boshoff to chief scientific officer l...

Bristol Myers prunes pipeline amid new round of cost cuts

Bristol Myers Squibb is ending work on a handful of assets, including an immunol...

Acelyrin and Alumis to merge in deal combining cash, as...

After running into clinical hurdles with its “diamond in the rough” strategy, Lo...

Sionna inks $191M IPO for cystic fibrosis pipeline as A...

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsiz...

Longtime Sandoz exec announces retirement; Lilly appoin...

→ Francisco Ballester is retiring as president, region international at Sandoz o...

Novo Nordisk takes aim at Roche in hemophilia A, but is...

Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in ...

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical busine...

Bioluminescence Ventures to shut down 15 months after l...

The life science investment firm Bioluminescence Ventures will close its doors l...

Doctors complete fourth xenotransplant of gene-edited p...

A 66-year-old man whose kidneys were failing is now the fourth person who has re...

Major FDA staff cuts would slow drug reviews, experts say

The Trump administration's reported plans to potentially lay off thousands of FD...

Sanofi, AstraZeneca back Teva's call to rehear case on ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellat...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.